• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Glenn J. Bubley, MD


  • Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE.Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates.J Clin Oncol. 2014 May 12.
  • Rojan A, Funches R, Regan MM, Gulley JL, Bubley GJ.Dramatic and prolonged PSA response after retreatment with a PSA vaccine.Clin Genitourin Cancer. 2013 Sep;11(3):362-4.
  • Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP.A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.Nat Genet. 2013 Jul;45(7):747-55.
  • Holupka E, Bubley GJ.Reply.Urology. 2013 Mar 9.
  • Bubley GJ, Bloch BN, Vazquez C, Genega E, Holupka E, Rofsky N, Kaplan I.Accuracy of Endorectal Magnetic Resonance/Transrectal Ultrasound Fusion for Detection of Prostate Cancer During Brachytherapy.Urology. 2013 Mar 9.
  • Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME.Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.Urology. 2013 Mar;81(3):611-6.
  • Sowalsky AG, Ye H, Bubley GJ, Balk SP.Clonal progression of prostate cancers from Gleason grade 3 to grade 4.Cancer Res. 2013 Feb 1;73(3):1050-5.
  • Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME.Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer.Clin Genitourin Cancer. 2012 Dec;10(4):232-8.
  • Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME.Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.BJU Int. 2012 Aug 29.
  • San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.J Urol. 2011 Feb;185(2):471-6.
  • Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI.Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer.J Clin Oncol. 2010 Mar 20;28(9):1496-501.
  • Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.Clin Cancer Res. 2009 Nov 15;15(22):7099-105.
  • Joshi MD, Ahmad R, Yin L, Raina D, Rajabi H, Bubley G, Kharbanda S, Kufe D.MUC1 oncoprotein is a druggable target in human prostate cancer cells.Mol Cancer Ther. 2009 Nov;8(11):3056-65.
  • Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG.Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.Urology. 2009 Nov;74(5):1156-61.
  • Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG.Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.Clin Cancer Res. 2009 Sep 15;15(18):5794-802.
  • Bhatt RS,Bubley GJ.The challenge of herbal therapies for prostate cancer.Clin Cancer Res. 2008 Dec 1;14(23):7581-2. Review.
  • Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ.Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.BJU Int. 2008 Aug;102(3):358-63.
  • Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.BJU Int. 2008 May;101(9):1084-9.
  • Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.J Clin Oncol. 2008 Mar 1;26(7):1148-59.
  • Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK.A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.Cancer. 2008 Feb 1;112(3):521-6.
  • Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ.A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.Clin Genitourin Cancer. 2007 Jun;5(5):323-8.
  • Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ, Ma J.Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer.Prostate. 2007 Sep 1;67(12):1354-61.
  • Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK.Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.J Urol. 2007 Jun;177(6):2146-50.
  • Masiello D, Mohi MG, McKnight NC, Smith B, Neel BG, Balk SP, Bubley GJ.Combining an mTOR Antagonist and Receptor Tyrosine Kinase Inhibitors for the Treatment of Prostate Cancer.Cancer Biol Ther. 2007 Feb;6(2):195-201.
  • Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM.Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.J Clin Oncol. 2006 Dec 1;24(34):5408-13.
  • Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A.Prostate cancer in a transgender woman 41 years after initiation of feminization.JAMA. 2006 Nov 15;296(19):2316-7.
  • Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP.Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15969-74.
  • Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML, Balk SP.Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.Am J Pathol. 2006 Aug;169(2):682-96.
  • Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ.The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.J Urol. 2006 Aug;176(2):520-5.
  • Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW.Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.J Clin Oncol. 2006 Jun 20;24(18):2723-8.
  • Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP.Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.Cancer Res. 2006 Mar 1;66(5):2815-25.
  • Jones GB, Crasto CF, Mathews JE, Xie L, Mitchell MO, El-Shafey A, D'Amico AV, Bubley GJ.An image contrast agent selectively activated by prostate specific antigen.Bioorg Med Chem. 2006 Jan 15;14(2):418-25.
  • Fu XS, Choi E, Bubley GJ, Balk SP.Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation.Prostate. 2005 May 15;63(3):215-21.
  • Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP.Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.Int J Cancer. 2005 Jan 20;113(3):490-8.
  • Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ.Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer.J Clin Oncol. 2004 Sep 15;22(18):3705-12.
  • George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ.Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.Urology. 2004 Feb;63(2):327-32.
  • Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ.Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.Clin Cancer Res. 2003 Aug 15;9(9):3282-7.
  • Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M.Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.Mol Cancer Res. 2003 Aug;1(10):707-15.
  • Balk SP, Ko YJ, Bubley GJ.Biology of prostate-specific antigen.J Clin Oncol. 2003 Jan 15;21(2):383-91.
  • Bubley GJ, Balk SP, Regan MM, Duggan S, Morrissey ME, Dewolf WC, Salgami E, Mantzoros C.Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.J Urol. 2002 Nov;168(5):2249-52.
  • Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP.Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.J Biol Chem. 2002 Jul 19;277(29):26321-6.
  • Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE.Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.Semin Oncol. 2001 Aug;28(4 Suppl 15):32-9.
  • Ko YJ, Bubley GJ.Prostate cancer in the older man.Oncology (Huntingt). 2001 Sep;15(9):1113-9, 1123-4; discussio.
  • Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA.Loss of IFN-gamma production by invariant NK T cells in advanced cancer.J Immunol. 2001 Oct 1;167(7):4046-50.
  • Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP.Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10823-8.
  • Bubley GJ.Is the flare phenomenon clinically significant?.Urology. 2001 Aug;58(2 Suppl 1):5-9.
  • Jones GB, Hynd G, Wright JM, Purohit A, Plourde GW, Huber RS, Mathews JE, Li A, Kilgore MW, Bubley GJ, Yancisin M, Brown MA.Target-directed enediynes: designed estramycins.J Org Chem. 2001 Jun 1;66(11):3688-95.
  • Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ.A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.Clin Cancer Res. 2001 Apr;7(4):800-5.
  • Jones GB, Mitchell MO, Weinberg JS, D'Amico AV, Bubley GJ.Towards enzyme activated antiprostatic agents.Bioorg Med Chem Lett. 2000 Sep 4;10(17):1987-9.
  • Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW.A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.Clin Cancer Res. 2000 May;6(5):1632-8.
  • Shaneyfelt T, Husein R, Bubley G, Mantzoros CS.Hormonal predictors of prostate cancer: a meta-analysis.J Clin Oncol. 2000 Feb;18(4):847-53.
  • Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP.Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.Cancer Res. 1999 Jun 1;59(11):2511-5.
  • Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP.Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.N Engl J Med. 1995 May 25;332(21):1393-8.
  • Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W.Detection of circulating tumor cells in men with localized prostate cancer.J Clin Oncol. 1994 Dec;12(12):2634-9.
  • Bubley GJ, Ashburner BP, Balk SP, Ara G, Varshaney A, Teicher BA.Identification of cis-diamminedichloroplatinum(II) adducts in DNA from drug-treated human cell nuclei.Biotechniques. 1992 May;12(5):694, 696, 698.
  • Bubley GJ, Chapman B, Chapman SK, Crumpacker CS, Schnipper LE.Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions.Antimicrob Agents Chemother. 1989 Jun;33(6):862-5.